Noninvavie Ventilation to Patients With COVID-19
Conditions
Keywords
noninvavie ventilation, COVID-19, respiratory failure
Brief summary
Noninvasive ventilation(NIV) is an important treatment to the respiratory failure patients.The severe Corona Virus Disease-19(COVID-19) patients are incline to respiratory failure.The NIV may reduce the intubtion rate.This research was taken to investigate the factor to the success of the noninvasive ventilation to the COVID-19 patients with respiratory failure.
Detailed description
Noninvasive ventilation(NIV) is an important treatment to the respiratory failure patients.The severe Corona Virus Disease-19(COVID-19) patients are incline to respiratory failure.The NIV may reduce the intubtion rate.This research was taken to investigate the factor to the success of the noninvasive ventilation to the COVID-19 patients with respiratory failure.We wish to raise the success rate to COVID-19 patients with respiratory failure.More critically ill COVID-19 patients could avoid the intubtion.
Interventions
DEVICEnoninvasive ventilation
noninvasive ventilation to support the COVID-19 patients with respiratory failure
Sponsors
The First Affiliated Hospital of Guangzhou Medical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Shortness of breath, RR\>30 times per minute; 2. At room air, SpO2 lower than 93%; 3. The partial pressure of Arterial blood oxygen (PaO2)/the fraction of inspired oxygen (FiO2) ≤ 300mmHg; 4. CT（computed tomography） chest imaging shows that lung damage develops significantly within 24 to 48 hours.
Exclusion criteria
1. Severe cardiovascular disease, 2. respiratory arrest, 3. cardiovascular instability (hypotension, arrhythmias, myocardial infarction), 4. change in mental status or patients who were uncooperative, high risk of aspiration, viscous or copious 5. secretions, 6. recent facial or gastroesophageal surgery, 7. craniofacial trauma, 8)fixed nasopharyngeal abnormalities, 9）burns, 10) extreme obesity.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| success rate | 4 month | the sucess rate of the noninvasive ventilation |
| the intubtion rate | 4 month | the intubtion rate of the COVID-19 patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| blood lymphocyte | 4month | blood lymphocyte of the COVID-19 patients |
| B-type natriuretic peptide | 4 month | blood B-type natriuretic peptide of the COVID-19 patients |
| Procalcitonin | 4 month | blood procalcitonin of the COVID-19 patients |
| Oxygen Saturation | 4 month | Oxygen Saturation of the COVID-19 patients |
Countries
China
Outcome results
None listed